Myelodysplastische Syndrome: klinisch relevante Aspekte in Diagnostik, Prognose und Prädiktion

myelodysplastische Syndrome - Diagnose - Prognose - Prädiktion

myelodysplastic syndromes - diagnosis - prognosis - prediction

Literatur

• 1 Bennett J M, Catovsky D, Daniel M T. et al . Proposals for the classification of the myelodysplastic syndromes.  Br J Haematol. 1982;  51 189-199
• 2 Cutler C S, Lee S J, Greenberg P. et al . A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.  Blood. 2004;  104 579-585
• 3 Della Porta M G, Malcovati L, Travaglino E. et al . A prognostic model for predicting the impact of comorbidities on survival of patients with Myelodysplastic Syndromes.  Blood. 2007;  118 (11) Abstract 2453, p723a
• 4 ESH International conference: Myelodysplastic Syndromes and Bone Marrow Failure. 15 – 18 May 2008 . Albufeira, Portugal;
• 5 Fenaux P, Mufti G J, Santini V. et al . Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.  Blood. 2007;  110 (1) abstract 817, p250a
• 6 Gattermann N, Billiet J, Kronenwett R. et al . High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600x109/L) and ringed sideroblasts more than 15 % considered as MDS/MPD, unclassifiable.  Blood. 2007;  109 (3) 1334-5
• 7 Germing U, Hildebrandt B, Pfeilstöcker M. et al . Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).  Leukemia. 2005;  19 2223-2231
• 8 Germing U, Strupp C, Kuendgen A. et al . Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.  Haematologica. 2006;  91 (12) 1596-604
• 9 Greenberg P, Cox C, LeBeau M M. et al . International scoring system for evaluating prognosis in myelodysplastic syndromes.  Blood. 1997;  89 2079-2088
• 10 Greenberg P, Anderson J, de Witte T. et al . Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.  J Clin Oncol. 2000;  18 (19) 3447-52
• 11 Haase, D, Germing U, Schanz J. et al . New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.  Blood. 2007;  110 4385-4395
• 12 Haase D, Estey E, Steidl C. et al . multivariate evaluation of the prognostic and therapeutic relevance of cytogenetics in a merged European-American Cohort of 3860 patients with MDS.  Blood. 2007;  110 (1) Abstract 247, p80a
• 13 Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G. et al . A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.  Br J Haematol. 2003;  120 (6) 1037-46
• 14 Jaffe E S, Harris N L, Stein H, Vardiman J W (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon; IARC Press 2001
• 15 Kantarjian H M, Issa J P, Rosenfeld C S. et al . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.  Cancer. 2006;  106 (8) 1794-803
• 16 Knipp S, Hildebrand B, Kündgen A. et al . Intensive chemotherapy is not recommended for patients aged > 60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.  Cancer. 2007;  110 (2) 345-52
• 17 List A, Dewald G, Bennett J. et al . Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.  N Engl J Med. 2006;  355 1456-1465
• 18 Malcovati L, Germing U, Kuendgen A. et al . A WHO classification based prognostic scoring system (WPSS) for predicting survival in Myelodysplastic Syndromes.  J Clin Oncol. 2007;  25 3503-3510
• 19 Nimer S. Myelodysplastic Syndromes.  lood. 2008;  111 4841-4851 Review
• 20 Nösslinger T, Reisner R, Koller E. et al . Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.  Blood. 2001;  98 (10) 2935-41
• 21 Oosterveld M, Muus P, Suciu S. et al . Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukaemia; two parallel studies adjusted for various prognostic factors.  Leukemia. 2002;  16 (9) 1615-21
• 22 Pfeilstöcker M, Reisner R, Nösslinger T. et al . Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics.  Br J Haematol. 1999;  106 (2) 455-63
• 23 Saunthararajah Y, Nakamura R, Wesley R, Wang Q J, Barrett A J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.  Blood. 2003;  102 3025-3027
• 24 Stauder R, Noesslinger T, Pfeilstöcker M, Sperr W R, Wimazal F, Krieger O, Valent P. Impact of Age and Comorbidity in Myelodysplastic Syndromes. JNCCN Oct 2008, in press
• 25 Valent P, Horny H P, Bennett J M. et al . Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.  Leuk Res. 2007;  31 (6) 727-736